Clovis Oncology (Clovis Oncology) Days Inventory : 130.66 (As of Sep. 2022)

View and export this data going back to 2011. Start your Free Trial

What is Clovis Oncology Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). Clovis Oncology's Average Total Inventories for the three months ended in Sep. 2022 was $12.3 Mil. Clovis Oncology's Cost of Goods Sold for the three months ended in Sep. 2022 was $8.6 Mil. Hence, Clovis Oncology's Days Inventory for the three months ended in Sep. 2022 was 130.66.

The historical rank and industry rank for Clovis Oncology's Days Inventory or its related term are showing as below:

CLVSQ's Days Inventory is not ranked ^*
in the Biotechnology industry.
Industry Median: 191.745
* Ranked among companies with meaningful Days Inventory only.

Clovis Oncology's Days Inventory declined from Sep. 2021 (195.81) to Sep. 2022 (130.66).

Inventory Turnover measures how fast the company turns over its inventory within a year. Clovis Oncology's Inventory Turnover for the three months ended in Sep. 2022 was 0.70.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Clovis Oncology's Inventory-to-Revenue for the three months ended in Sep. 2022 was 0.40.

Clovis Oncology Days Inventory Historical Data

The historical data trend for Clovis Oncology's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clovis Oncology Days Inventory Chart

Clovis Oncology Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Days Inventory

Get a 7-Day Free Trial

855.45

451.25

281.97

252.88

208.71

Clovis Oncology Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Days Inventory	Get a 7-Day Free Trial															195.81	145.20	136.65	137.33	130.66

Competitive Comparison of Clovis Oncology's Days Inventory

For the Biotechnology subindustry, Clovis Oncology's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clovis Oncology's Days Inventory Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clovis Oncology's Days Inventory distribution charts can be found below:

* The bar in red indicates where Clovis Oncology's Days Inventory falls into.

Clovis Oncology Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Clovis Oncology's Days Inventory for the fiscal year that ended in Dec. 2021 is calculated as

	Days Inventory (A: Dec. 2021 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (A: Dec. 2020 )	+	Total Inventories (A: Dec. 2021 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2021 )	*	Days in Period
=	( (30.714	+	13.688)	/	2 )	/	38.826	*	365
=	22.201					/	38.826	*	365
=	208.71

Clovis Oncology's Days Inventory for the quarter that ended in Sep. 2022 is calculated as:

	Days Inventory (Q: Sep. 2022 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (Q: Jun. 2022 )	+	Total Inventories (Q: Sep. 2022 ))	/	count )	/	Cost of Goods Sold (Q: Sep. 2022 )	*	Days in Period
=	( (13.232	+	11.419)	/	2 )	/	8.608	*	365 / 4
=	12.3255					/	8.608	*	365 / 4
=	130.66

Clovis Oncology (OTCPK:CLVSQ) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Clovis Oncology's Inventory Turnover for the three months ended in Sep. 2022 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	8.608	/	12.3255
	=	0.70

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Clovis Oncology's Inventory to Revenue for the three months ended in Sep. 2022 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	12.3255	/	30.663
	=	0.40

Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.

Clovis Oncology Days Inventory Related Terms

Thank you for viewing the detailed overview of Clovis Oncology's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Clovis Oncology (Clovis Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clovis Oncology Inc (OTCPK:CLVSQ) » Definitions » Days Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

5500 Flatiron Parkway, Suite 100, Boulder, CO, USA, 80301

Website

https://www.clovisoncology.com

Clovis Oncology Inc is a biopharmaceutical company. It is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, the EU, and additional international markets. The firm targets its development programs for the treatment of specific subsets of cancer populations. Its product candidate includes Rucaparib. Rucaparib is an oral small molecule inhibitor of poly ADP-ribose polymerase, is marketed in the United States for two indications specific to the recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. The company has two segments U.S and ex-U.S based on geograhic areas, with majority of its revenue coming from U.S.

Executives

Thomas C. Harding	officer: See Remarks	5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80301
Gillian C Ivers-read	officer: See Remarks	C/O PHARMION CORPORATION, 2525 28TH STREET, BOULDER CO 80301
Lindsey Rolfe	officer: See remarks	C/O CLOVIS ONCOLOGY, INC., 499 ILLINOIS STREET, SUITE 200, SAN FRANCISCO CA 94158
Daniel W Muehl	officer: See remarks	5 BILLERICA PARK, 101 BILLERICA AVE, NORTH BILLERCA MA 01862
Paul Edward Gross	officer: See Remarks	5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80302
Ronit Simantov	director	1988 CHAPEL STREET, NEW HAVEN CT 06515
James C Blair	director	5880 PACIFIC CENTER BLVD, SAN DIEGO CA 92121-4204
Patrick J Mahaffy	director, officer: President and CEO	C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80301
Thorlef Spickschen	director	TRAUBENWEG 25, 64342 SEEHEIN-JUGENHEIM 2M 00000
Richard A. Fair	director	C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Robert Azelby	director	307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109
Hooks Corwin Dale	officer: See remarks	C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, BOULDER CO 80301
Paul H Klingenstein	director	428 UNIVERSITY AVE, C/O ACCEL PARTNERS, PALO ALTO CA 94301
Ginger L Graham	director	AMYLIN PHARMACEUTICALS, INC., 885 ARAPAHOE AVENUE, BOULDER CO 80302
Brian G Atwood	director	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104